Physician profile
Anna P Mackender
NPI 1285862284
$7,601.05
in general payments reported to CMS, 2019-2025
26 companies · $2,794 in 2025
The $2,794 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $210 · 2021: $362 · 2022: $644 · 2023: $1,194 · 2024: $1,536 · 2025: $2,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,513 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,512.83 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $984.18 | 2021-2025 | |
| Lundbeck LLC | $820.06 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $793.53 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $734.89 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $585.17 | 2019-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $495.89 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $432.00 | 2019-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $372.81 | 2022-2025 | Azstarys |
| Tris Pharma INC | $293.38 | 2023-2025 | Dyanavel Xr, Quillivant |
| Teva Pharmaceuticals USA, INC. | $273.21 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Allergan, INC. | $246.41 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $227.86 | 2019-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $196.73 | 2020-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $184.11 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $169.94 | 2023-2025 | Aristada, Lybalvi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $158.64 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $143.85 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $124.44 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $120.71 | 2019-2025 | Trintellix |
| Shire North American Group INC | $66.93 | 2019 | |
| Neuronetics, INC. | $59.50 | 2023-2024 | Neurostar Tms Therapy System |
| Vertical Pharmaceuticals, LLC | $57.04 | 2019 | |
| Neos Therapeutics, LP | $17.67 | 2024 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $15.46 | 2019 | |
| Tempus Ai, INC | $15.33 | 2024 | |
| Owp Pharmaceuticals, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Mackender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.